People in the study receive zigakibart during the extension period, which means treatment continues after the earlier trial has ended. The study follows participants over time to see how they do with ongoing treatment and to collect information about side effects, blood and urine test results, and other health checks. It also looks at how the body handles the medicine and whether the immune system makes proteins that react to it.

Because this is a long-term extension study, the main focus is continued treatment and follow-up rather than changing between different medicines. The study is designed to gather more safety information while participants remain on zigakibart.

Participants in the study will be randomly assigned to receive either Sparsentan or an ARB. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are not biased. The study will also include a period where participants can receive Sparsentan openly, allowing researchers to assess its long-term effects. Additionally, some participants may be involved in a sub-study to evaluate the combination of Sparsentan with another medication called Dapagliflozin, which is used to manage blood sugar levels in people with diabetes.

The trial will monitor changes in the amount of protein in the urine and kidney function over time. Participants will take the medication in tablet form by mouth. The study will last for several months, with regular check-ups to ensure the safety and effectiveness of the treatment. The goal is to gather information that could lead to better treatment options for people with IgAN.

The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.

The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.

Several supportive medications may be used during the study, including Desloratadine, Diphenhydramine, Cetirizine, Fexofenadine, Paracetamol, Methylprednisolone, Levocetirizine, Loratadine, and Famotidine. These medications are used to manage potential side effects or symptoms that participants might experience during the treatment. A Saline solution will also be used as part of the treatment process.

The purpose of this research is to evaluate how effective Felzartamab is compared to placebo in reducing the amount of protein in the urine of people with IgA Nephropathy. The study will last several years, during which participants will receive regular infusions of either Felzartamab or placebo, and their kidney function will be monitored through various tests.

The purpose of this study is to evaluate how safe atacicept is and how well it works in reducing the amount of protein in the urine. The medication is given as a subcutaneous injection using a pre-filled syringe. Participants will receive treatment while continuing their regular standard of care medications as prescribed by their doctors.

The study will last for 52 weeks, during which participants will receive regular doses of atacicept. Throughout the study, doctors will monitor various aspects of kidney function, particularly the amount of protein in the urine and how well the kidneys are filtering blood. They will also track the levels of specific disease markers in the blood that are associated with each type of kidney disease.

The purpose of the study is to understand how Ravulizumab works in the body and how safe and effective it is for treating IgAN in children. The study will involve giving the medication to participants and monitoring them over a period of time to see how their bodies respond to the treatment. This will help researchers learn more about the medication’s effects and how it can be used to treat this kidney disease in children.

Participants in the study will receive the medication and be observed by healthcare professionals to ensure their safety and to gather information about the treatment’s impact. The study aims to provide valuable insights that could help improve treatment options for children with IgAN in the future.

The purpose of the study is to determine if Budesonide is more effective than a placebo and if it works better than Prednisone in reducing proteinuria, which is the presence of excess protein in the urine. Participants in the study will receive one of these treatments and will be monitored over a period of time to assess changes in their condition. The study will also look at the number of side effects and any changes in kidney function during the treatment period.

Throughout the study, children will be given either Budesonide, Prednisone, or a placebo and will be observed for 24 weeks. The main goal is to see how much the protein levels in their urine decrease by the end of the treatment compared to the beginning. The study will also track any side effects and changes in kidney function to ensure the safety and effectiveness of the treatments being tested.

Participants in the study will be randomly assigned to receive either Iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a total of 24 months, with an interim analysis at 9 months to assess the initial effects of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and the progression of their kidney disease. The main focus will be on measuring protein levels in the urine, which is an indicator of kidney function, and observing any changes in kidney function over time. The study aims to determine if Iptacopan can reduce protein levels in the urine and slow down the progression of IgA Nephropathy compared to the placebo. Participants will also be monitored for any side effects or adverse reactions to the treatment.

Participants in the study will be randomly assigned to receive either atrasentan or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for a period of time, during which participants will have regular check-ups to monitor their kidney function and overall health. There is also an open-label extension phase, where all participants can receive atrasentan to further assess its safety.

The main goal is to see if atrasentan can help reduce protein levels in the urine and slow down the progression of kidney damage. Participants will be closely monitored throughout the study to ensure their safety and to gather information on how the treatment affects their condition. This study aims to provide valuable insights into the potential benefits of atrasentan for people with IgA Nephropathy.

The purpose of the study is to see if hydroxychloroquine can help slow down the decrease in kidney function over a period of three years in patients with IgA nephropathy. Participants in the study will receive either hydroxychloroquine or a placebo and will be monitored regularly to assess their kidney function and overall health. The study will also look at other health markers such as protein levels in urine, blood pressure, and any side effects experienced by the participants.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their condition. The study aims to provide valuable information on whether hydroxychloroquine can be an effective treatment option for people with IgA nephropathy, potentially improving their quality of life and slowing the progression of the disease.

Participants in the study will receive either Ravulizumab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of time, during which participants will be monitored to see how their condition responds to the treatment. The main focus will be on changes in protein levels in the urine, which is a key indicator of kidney health. Other aspects of kidney function and overall health will also be assessed.

This study is designed to help understand whether Ravulizumab can improve the health of people with Lupus Nephritis or Immunoglobulin A Nephropathy. By comparing the effects of the medication to a placebo, researchers aim to gather important information that could lead to better treatment options for these kidney diseases in the future.

The purpose of this study is to ensure that iptacopan is safe and well-tolerated over a longer period. Participants will take iptacopan in the form of hard gelatin capsules, which are taken orally. The study will also involve other medications, such as ACE inhibitors and angiotensin II receptor blockers (ARBs), which are commonly used to manage blood pressure and protect kidney function. These medications may be used alone or in combination, depending on the participant’s needs.

Throughout the study, participants will be monitored for any side effects or changes in their health. The study will last for a maximum of 96 weeks, during which time participants will have regular check-ups to assess their kidney function and overall health. The goal is to gather information on how well participants tolerate iptacopan over time and to ensure its safety for long-term use in managing IgA nephropathy.

Participants in the study will be randomly assigned to receive either the ALXN 2050 tablets or placebo tablets. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, during which participants will be monitored for changes in their condition and any side effects they may experience.

The trial aims to find the most effective dose of ALXN 2050 for treating these kidney diseases. Participants will have regular check-ups to assess their kidney function and overall health. The study will also look at how the medication affects the body and its safety. The ultimate goal is to determine if ALXN 2050 can be a beneficial treatment option for people with Lupus Nephritis or Immunoglobulin A Nephropathy.

Participants in the study will receive Sparsentan once daily for a period of 108 weeks. During this time, researchers will monitor the safety of the medication and observe any changes in the levels of protein in the urine, which is a key indicator of kidney health. The study aims to understand how well Sparsentan works in reducing protein levels in the urine and how the body processes the medication over time.

The study will also look at how many participants experience a complete or partial remission of their kidney disease symptoms, such as a significant reduction in protein levels in the urine. Additionally, researchers will track any side effects that occur during the study, including any that might lead to stopping the treatment. This information will help determine the overall safety and potential benefits of Sparsentan for treating these specific kidney diseases in children.

Participants in the study will receive the treatment with ravulizumab over a period of six months. During this time, the study will monitor changes in the levels of protein and blood in the urine to assess the effectiveness of the treatment. The study will also look at how the treatment affects kidney function and whether any side effects occur. After the six-month treatment period, participants will continue to be observed for an additional four months to see how their condition evolves after stopping the medication.

This study aims to provide valuable information on the safety and effectiveness of ravulizumab for treating IgA nephropathy in patients who have not had success with other treatments. The results could help improve understanding of how to manage this challenging condition and offer new hope for those affected by it.

The purpose of the study is to assess how effective ravulizumab is compared to a placebo in reducing the amount of protein in the urine, a condition known as proteinuria, and in slowing down the decline of kidney function over time. Participants in the study will receive either ravulizumab or a placebo, and their kidney function will be monitored throughout the study period. The study will involve regular check-ups and assessments to track changes in kidney health and overall well-being.

Participants will be involved in the study for a period of time, during which they will receive the treatment and undergo various tests to measure the effects on their kidney function. The study aims to provide valuable information on whether ravulizumab can be a beneficial treatment option for people with IgAN, potentially leading to better management of the disease and improved quality of life for those affected.

Participants in the study will receive either the RO7434656 treatment or a placebo through injections. The study will last for several weeks, during which time the participants’ health and kidney function will be closely monitored. The main goal is to see if the treatment can lower the amount of protein in the urine, which is measured by the urine protein-to-creatinine ratio (UPCR). This will help determine if the treatment is effective in slowing down the disease.

Throughout the study, participants will have regular check-ups to assess their kidney function and overall health. The study will also look at other factors, such as changes in fatigue levels and any side effects that may occur. By the end of the study, researchers hope to gather enough information to understand the safety and effectiveness of RO7434656 in treating Primary IgA Nephropathy.

The purpose of the study is to determine if atrasentan is safe and effective for people with IgA nephropathy who are already taking an SGLT2 inhibitor. Participants will be randomly assigned to receive either atrasentan or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will follow a crossover design, where participants will switch from one treatment to the other during the study period.

The study will last for several weeks, with participants undergoing regular check-ups and tests to monitor their health and the effects of the treatment. The main focus will be on changes in protein levels in the urine, which is an important indicator of kidney function. By the end of the study, researchers hope to gather valuable information about the potential benefits and safety of atrasentan for treating IgA nephropathy.

Participants in the study will receive Sibeprenlimab through an injection under the skin, known as a subcutaneous injection. The study will monitor participants over a period of time to observe any side effects and to assess how well the treatment is tolerated. The study will also look at how the treatment affects kidney function over time, using measures such as the estimated glomerular filtration rate (eGFR), which is a test to check how well the kidneys are working, and the amount of protein in the urine, which can indicate kidney damage.

The trial will last for several years, allowing researchers to gather comprehensive data on the effects of Sibeprenlimab. This information will help determine if the treatment is safe and effective for long-term use in managing IgAN. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to collect necessary data for the research.

The purpose of the study is to assess the effectiveness and safety of Sibeprenlimab in treating IgAN. Participants in the trial will receive either Sibeprenlimab or a placebo, in addition to their standard care, for a period of nine months. The trial will monitor changes in the levels of protein in the urine, which is a key indicator of kidney function. The study will also track the overall health and kidney function of participants over a longer period to gather more information about the treatment’s impact.

Throughout the trial, participants will undergo regular check-ups and tests to ensure their safety and to collect data on how well the treatment is working. The trial aims to provide valuable insights into whether Sibeprenlimab can be an effective treatment option for people with IgAN, potentially improving their kidney health and quality of life.

Participants in the study will receive one of the treatments being tested, which may include medications like Ramipril, Losartan, Methylprednisolone, Prednisone, or Dapagliflozin. Some participants may receive a placebo. The study will observe the effects of these treatments on the amount of protein in the urine, which is a sign of kidney damage, and on kidney function over time. The study will last for several months, with regular check-ups to monitor the participants’ health and the effectiveness of the treatments.

The purpose of this study is to find out which treatment approach is more effective in reducing protein levels in the urine and improving kidney function in patients with IgAN. By comparing these different treatments, researchers hope to provide better care options for people living with this kidney disease.